(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.38%) $966.30
(-0.36%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.36%) $91.45
Live Chart Being Loaded With Signals
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases...
Stats | |
---|---|
今日成交量 | 4 508.00 |
平均成交量 | 18 285.00 |
市值 | 19.74M |
EPS | $0 ( 2024-04-05 ) |
下一个收益日期 | ( $-2.89 ) 2024-06-11 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.400 |
ATR14 | $0.117 (1.67%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-04 | Trachtenberg Eric | Buy | 4 600 | Common Stock |
2024-01-04 | Trachtenberg Eric | Sell | 1 227 | Common Stock |
2024-01-04 | Trachtenberg Eric | Buy | 20 500 | Stock Option (right to buy) |
2024-01-04 | Kharabi Darius | Buy | 4 600 | Common Stock |
2024-01-04 | Kharabi Darius | Sell | 1 385 | Common Stock |
INSIDER POWER |
---|
92.84 |
Last 100 transactions |
Buy: 1 301 269 | Sell: 48 062 |
Kala Pharmaceuticals Inc 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-303 000 (0.00 %) |
EPS: | $-17.35 |
FY | 2023 |
营收: | $0 |
毛利润: | $-303 000 (0.00 %) |
EPS: | $-17.35 |
FY | 2022 |
营收: | $3.89M |
毛利润: | $1.33M (34.22 %) |
EPS: | $-0.150 |
FY | 2021 |
营收: | $11.24M |
毛利润: | $7.14M (63.55 %) |
EPS: | $-136.13 |
Financial Reports:
No articles found.
Kala Pharmaceuticals Inc
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development products comprise KPI-287 that inhibits the vascular endothelial and platelet derived growth factors for the treatment of retinal diseases, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion; and selective glucocorticoid receptor modulators program, a novel class of compounds to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。